BioSpace News Archive

What’s New: Intel Labs and the Perelman School of Medicine at the University of Pennsylvania are co-developing technology to enable a federation of 29 international healthcare and research institutions led by Penn Medicine to train artificial intelligence models that identify brain tumors using a privacy-preserving technique called federated learning.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today unveiled its COVID-19 Risk Mitigation offering, which leverages the company’s significant experience with global viral outbreaks as well as cGMP inspection and CMC review processes to ensure that manufacturers can safely and confidently continue operations through the COVID-19 pandemic.

A new research study published in Current Developments in Nutrition found that the equivalent of one cup of fresh blueberries, given as 22 g of freeze-dried blueberries, may beneficially affect areas of health in overweight men with type 2 diabetes.

Aspenstate has received clearance for their portable x-ray system, AiRTouch, from the U.S. Food and Drug Administration (FDA).

Tenaya Therapeutics, Inc., a company with a mission to discover, develop, and deliver potentially curative therapies that target the underlying causes of heart disease, today announced that it will present preclinical data from four studies as posters at the 23 rd Annual Meeting of the American Society of Gene & Cell T

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that Dr. Tapan Maniar has been appointed SVP and Head of Clinical Development and will join the senior team

LHC Group, Inc. (NASDAQ: LHCG) announced today that the Company is presenting at the BofA Securities 2020 Virtual Health Care Conference on Tuesday, May 12, 2020.

Augmedix now offers two tiers of best-in-class medical documentation services so clinicians can focus less on administrative tasks and more on what matters most: patient care.

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, provided a clinical program update and reported financial results for the first quarter ended March 31, 2020.

LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, reported financial results for the quarter ended March 31, 2020 and provided a business update.